Exelixis
EXEL
#2109
Rank
ยฃ5.74 B
Marketcap
ยฃ20.13
Share price
-1.53%
Change (1 day)
15.14%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Exelixis (EXEL) Fails to deliver data

Key failure to deliver metrics for Exelixis:

A Failure to deliver also known as fails-to-deliver or FTD occurs when a buyer or seller is unable to meet his trading obligations. FTDs for US listed companies are reported to the SEC and published twice a month. Therefore there is a certain delay between the reporting and the publishing of the data.

Failures to deliver for Exelixis (EXEL) - 3 months history

Number of shares, 3 months chart

Biweekly Failures to deliver volume for Exelixis (EXEL) - since 2013

Volume in USD (price x number of shares), data since 2013

Exelixis (EXEL) Failure to deliver volume, Year over Year

Year Volume (Price x Shares) Change
2024ยฃ8.96 M38.21%
2023ยฃ6.48 M-41.81%
2022ยฃ11.14 M-31.9%
2021ยฃ16.36 M-20.71%
2020ยฃ20.64 M303.63%
2019ยฃ5.11 M-70.5%
2018ยฃ17.33 M8.82%
2017ยฃ15.92 M-17.35%
2016ยฃ19.27 M-75.68%
2015ยฃ79.23 M19.37%
2014ยฃ66.37 M258.49%
2013ยฃ18.51 M

FTD volume in the last 3 months for similar companies or competitors

Company FTD volume (3months) FTD volume (1 year) Country
ยฃ22.53 Mยฃ43.31 M๐Ÿ‡ฌ๐Ÿ‡ง UK
ยฃ3.41 Mยฃ70.14 M๐Ÿ‡ซ๐Ÿ‡ท France
ยฃ39.92 Mยฃ95.81 M๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ36.47 Mยฃ0.31 B๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ87.32 Mยฃ0.26 B๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ90.55 Mยฃ0.28 B๐Ÿ‡บ๐Ÿ‡ธ USA
ยฃ0.24 Bยฃ0.50 B๐Ÿ‡บ๐Ÿ‡ธ USA
N/Aยฃ0.06 M๐Ÿ‡บ๐Ÿ‡ธ USA
N/Aยฃ0.04 M๐Ÿ‡บ๐Ÿ‡ธ USA